Schizophrenia

Lancet

Volumn 353, Issue 9162, 1999, Pages 1425-1430

  Schultz, Susan K ^a   Andreasen, Nancy C ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST;

CEREBELLUM; DELUSION; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYNDROME; FRONTAL CORTEX; GENETIC SUSCEPTIBILITY; HALLUCINATION; HIPPOCAMPUS; HUMAN; INHERITANCE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; REVIEW; SCHIZOPHRENIA; SYMPTOM; TEMPORAL CORTEX; THALAMUS;

EID: 0033599714     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07549-7     Document Type: Review

References (42)

1. Knapp M. Costs of schizophrenia. Br J Psychiatry. 171:1997;509-518.
2. Salit S.A., Kuhn E.M., Hartz A.J., Vu J.M., Mossa A.L. Hospitalization costs associated with homelessness in New York City. N Engl J Med. 338:1998;1734-1740.
3. International classification of diseases. 10th:1994;WHO, Geneva.
4. Diagnostic and statistical manual of mental disorders. 4th:1994;American Psychiatric Press, Washington, DC. DSM-IV.
5. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry. 153:1996;321-330.
6. Hull J.W., Smith T.E., Anthony D.T.et al. Patterns of symptom change: a longitudinal analysis. Schizophr Res. 24:1997;17-18.
7. McGuffin P., Owen M.J., Farmer A.E. Genetic basis of schizophrenia. Lancet. 346:1996;678-682.
8. Geddes J.R., Lawrie S.M. Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry. 167:1995;786-793.
9. Verdoux H., Geddes J.R., Takei N.et al. Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am J Psychiatry. 154:1997;1220-1227.
10. Moldin S.O., Gottesman I.I. At issue: genes, experience and chance in schizophrenia: positioning for the 21st century. Schizophr Bull. 23:1997;547-561.
11. Turecki G., Rouleau G.A., Joober R., Mari J., Morgan K. Schizophrenia and chromosome 6. Am J Med Genet. 74:1997;195-198.
12. Levinson D.F., Mahtani M.M., Nancarrow D.J. Genome scan of schizophrenia. Am J Psychiatry. 155:1998;741-750.
13. Freedman R. Basic and clinical approaches to the genetics of deficits in schizophrenia. Biol Psychiatry. 43(suppl 8S):1998;3S.
14. Arnold S.E., Trojanowski J.Q., Gur R.E., Blackwell P., Han L.Y., Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry. 55:1998;225-232.
15. Ward K.E., Friedman L., Wise A., Schulz S.C. Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res. 22:1996;197-223.
16. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia: a systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry. 172:1998;110-120.
17. Lim K.O., Tew W., Kushner M.et al. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry. 153:1996;1548-1553.
18. Schlaepfer T.E., Harris G.J., Tien A.Y.et al. Diseased regional cortical gray matter volume in schiozphrenia. Am J Psychiatry. 151:1994;842.
19. McGuire P.K., Silbersweig D.A., Wright I.et al. The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. Br J Psychiatry. 169:1996;148-159.
20. Silbersweig D.A., Stern E., Frith C.et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 378:1995;176-179.
21. Buchsbaum M.S., Haier R.J., Potkin S.G.et al. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 49:1992;935-942.
22. Buchsbaum M.S., Someya T., Teng C.Y.et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry. 153:1996;191-199.
23. Andreasen N.C. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science. 275:1996;1586-1593.
24. Gur R.C., Gur R.E. Hypofrontality in schizophrenia: RIP. Lancet. 345:1995;1383-1384.
25. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S., Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 378:1995;180-182.
26. Abi-Dargham A., Gil R., Krystal J.et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 155:1998;761-767.
27. Yurgelun-Todd D.A., Waternaux C.M., Cohen B.M.et al. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry. 153:1996;200-205.
28. Lim K.O., Hedehus M., de Crespigny A., Menon V., Moseley M. Diffusion tensor imaging of white matter tracts in schizophrenia. Biol Psychiatry. 43(suppl 8S):1998;11S.
29. Deicken R.F., Pegues M., Amend D., Bloomer C., Weiner M. Hippocampal neuronal loss in schizophrenia as measured by proton MRSI. Biol Psychiatry. 43(supple 8S):1998;25S.
30. Williamson R., Bartha R., Drost D. 1H-MRS Imaging of glutamate and glutamine in schizophrenic patients. Biol Psychiatry. 43(suppl 8S):1998;7S.
31. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol. 12:1998;21-36.
32. Kane J., Honingfeld G., Singer J.et al. Clozapine for treatment-resistant schizophrenia. Arch Gen Psychiatry. 45:1988;789-796.
33. Essock S.M., Hargreaves W.A., Covell N.H., Goethe J. Antipsychotics in research and clinical settings. Psychopharmacol Bull. 32:1996;683-697.
34. Rosenheck R., Cramer J., Xu W.et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 337:1997;809-815.
35. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W. Positive and negative symptom response to clozapine in schizophrenia. 1998; 155: 751-60.
36. Davis J.M., Janicak P.G. Risperidone: a new, novel (and better?) antipsychotic. Psychiatr Ann. 26:1996;78-87.
37. Jeste D.V., Eastham J.H., Lacro J.P.et al. Management of late-life psychosis. J Clin Psychiatry. 57:1996;39-45.
38. Schooler N.R. New antipsychotic medications: strategies for evaluation and selected findings. Schizophr Res. 27:1997;249-259.
39. Beasley C.M., Tollefson G., Tran P.et al. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology. 14:1996;111-123.
40. Meats P. Quetiapine (Seroquel): an effective and well-tolerated atypical antipsychotic. Intl J Psychiatr Clin Pract. 1:1997;231-239.
41. Lehman A.F., Steinwachs D.M., Dixon L.B.et al. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 24:1998;1-20.
42. Drury V., Birchwood M., Cochrane R., Macmillian F. Cognitive therapy and recovery from acute psychosis: a controlled trial I impact on psychotic symptoms and II impact on recovery time. Br J Psychiatry. 169:1996;593-607.